Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA date
TITLE: Capricor outlines 2027 manufacturing validation as Deramiocel BLA heads toward Nov. 22 PDUFA date
Capricor Therapeutics is approaching a critical regulatory milestone as the United States Food and Drug Administration continues its evaluation of the Biologics License Application for Deramiocel. The agency has established a Prescription Drug User Fee Act target action date of November 22, 2026, for the therapy. This specific application focuses on the treatment of upper limb impairment in individuals diagnosed with Duchenne muscular dystrophy who are at least nine years of age. As the review process moves forward, the company has also provided a roadmap for its production capabilities, projecting that manufacturing validation will be completed by 2027.
Hope-3 Efficacy and Clinical Data
The submission to the federal regulators includes comprehensive data from the HOPE-3 clinical trial. According to the company, the study successfully reached its primary efficacy endpoint using the Performance of the Upper Limb 2.0 scale. The results demonstrated a statistically significant p-value of 0.029, showing a 1.1-point improvement in patients receiving the treatment compared to those in the placebo group. To strengthen the application, Capricor provided an amendment that incorporated several layers of clinical evidence. This package includes data from long-term extension studies as well as robustness analyses designed to verify the consistency of the findings. Furthermore, the company integrated efficacy results from both the HOPE-2 and HOPE-3 trials to provide a more complete picture of the potential benefits of Deramiocel for the DMD patient population.
San Diego Facility and Manufacturing
Regarding the physical production of the therapy, Capricor confirmed that its specialized facility located in San Diego is currently prepared to handle the requirements for an initial commercial launch. While the company is navigating an ongoing arbitration process, management stated that they do not anticipate this legal matter will interfere with their ability to deliver the treatment to patients upon approval. Looking further ahead, the company is planning for the future of its production line by outlining a manufacturing validation schedule that extends into 2027. This long-term strategy is intended to ensure that the supply chain remains robust as the product moves from its initial release into broader distribution.
Financial Position and Commercial Spending
On the financial front, Capricor reported a strong balance sheet to support its upcoming operational goals. The firm currently holds approximately $198.5 million in cash and various securities. Based on current projections, leadership believes these assets are sufficient to fund company operations for a minimum of 12 months. As the PDUFA date nears, the organization is carefully managing its commercial expenditures to align with the expected launch timeline. By pacing its spending, the company aims to maintain financial stability while preparing the necessary infrastructure to support Deramiocel if the FDA grants marketing authorization this November.
Source: seekingalpha.com · 2026-11-11